Literatur: Operative Eingriffe unter Antikoagulation

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

  • 1. Douketis JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood 2011; 117:5044. [PubMed 21415266]
  • 2. Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol 2003; 123:676. [PMC 2689453]
  • 3. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery The Thromboprophylaxis Collaborative Group. Lancet 1993; 341:259. [PubMed 8093915]
  • 4. Jaffer AK. Perioperative management of warfarin and antiplatelet therapy. Cleve Clin J Med 2009; 76 Suppl 4:S37. [PubMed 19880835]
  • 5. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27:1760. [PubMed 8841325]
  • 6. Jørgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996; 27:1765. [PubMed 8841326]
  • 7. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S-592S. [PubMed 18574273]
  • 8. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449. [PubMed 8018000]
  • 9. Hull RD, Carter CJ, Jay RM, et al. The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation 1983; 67:901. [PubMed 6825247]
  • 10. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2:515. [PubMed 2863541]
  • 11. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74:606. [PubMed 8584992]
  • 12. Coon WW, Willis PW 3rd. Recurrence of venous thromboembolism. Surgery 1973; 73:823. [PubMed 4703485]
  • 13. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 1992; 340:873. [PubMed 1357297]
  • 14. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336:1506. [PubMed 9154771]
  • 15. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol 1986; 43:71. [PubMed 3510609]
  • 16. Lip GY, Lowe GD. ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. BMJ 1996; 312:45. [PubMed 8555864]
  • 17. Lip GY. Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy. Postgrad Med J 1996; 72:731. [PubMed 9015466]
  • 18. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336:251. [PubMed 8995087]
  • 19. Nixon JV. Left ventricular mural thrombus. Arch Intern Med 1983; 143:1567. [PubMed 6347112]
  • 20. Otley CC. Continuation of medically necessary aspirin and warfarin during cutaneous surgery. Mayo Clin Proc 2003; 78:1392. [PubMed 14601698]
  • 21. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78:2337. [PubMed 8950773]
  • 22. Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 1995; 108:276S. [PubMed 7555182]
  • 23. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003; 163:901. [PubMed 12719198]
  • 24. De Caterina R, Husted S, Wallentin L, et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007; 28:880. [PubMed 17426080]
  • 25. Wysokinski WE, McBane RD, Daniels PR, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc 2008; 83:639. [PubMed 18533080]
  • 26. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S. [PubMed 18574265]
  • 27. McIntyre H. Management, during dental surgery, of patients on anticoagulants. Lancet 1966; 2:99. [PubMed 4161034]
  • 28. Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med 1998; 158:1610. [PubMed 9701094]
  • 29. Malden N. Dental procedures can be undertaken without alteration of oral anticoagulant regimen. Evid Based Dent 2005; 6:11. [PubMed 15789043]
  • 30. Blinder D, Manor Y, Martinowitz U, Taicher S. Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INR value with occurrence of postoperative bleeding. Int J Oral Maxillofac Surg 2001; 30:518. [PubMed 11829234]
  • 31. Garcia-Darennes F, Darennes J, Freidel M, Breton P. [Protocol for adapting treatment with vitamin K antagonists before dental extraction]. Rev Stomatol Chir Maxillofac 2003; 104:69. [PubMed 12750622]
  • 32. Perry DJ, Noakes TJ, Helliwell PS, British Dental Society. Guidelines for the management of patients on oral anticoagulants requiring dental surgery. Br Dent J 2007; 203:389. [PubMed 17934422]
  • 33. Sindet-Pedersen S, Ramström G, Bernvil S, Blombäck M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med 1989; 320:840. [PubMed 2648144]
  • 34. Webster K, Wilde J. Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations. Br J Oral Maxillofac Surg 2000; 38:124. [PubMed 12054729]
  • 35. Souto JC, Oliver A, Zuazu-Jausoro I, et al. Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study. J Oral Maxillofac Surg 1996; 54:27. [PubMed 8530996]
  • 36. Patatanian E, Fugate SE. Hemostatic mouthwashes in anticoagulated patients undergoing dental extraction. Ann Pharmacother 2006; 40:2205. [PubMed 17090725]
  • 37. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:299S. [PubMed 18574269]
  • 38. Kovich O, Otley CC. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. J Am Acad Dermatol 2003; 48:233. [PubMed 12582394]
  • 39. Alcalay J, Alkalay R. Controversies in perioperative management of blood thinners in dermatologic surgery: continue or discontinue? Dermatol Surg 2004; 30:1091. [PubMed 15274698]
  • 40. Nelms JK, Wooten AI, Heckler F. Cutaneous surgery in patients on warfarin therapy. Ann Plast Surg 2009; 62:275. [PubMed 19240524]
  • 41. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322:1260. [PubMed 2183055]
  • 42. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995; 122:40. [PubMed 7985894]
  • 43. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112:423. [PubMed 2178534]
  • 44. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343:886. [PubMed 7908358]
  • 45. Collins LJ, Silverman DI, Douglas PS, Manning WJ. Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. Circulation 1995; 92:160. [PubMed 7600646]
  • 46. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633. [PubMed 8782752]
  • 47. Larson BJ, Zumberg MS, Kitchens CS. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk. Chest 2005; 127:922. [PubMed 15764777]
  • 48. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008; 109:918. [PubMed 18946305]
  • 49. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110:1658. [PubMed 15364803]
  • 50. Spandorfer JM, Lynch S, Weitz HH, et al. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84:478. [PubMed 10468095]
  • 51. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 2004; 125:1642. [PubMed 15136371]
  • 52. POLLER L, THOMSON J. EVIDENCE FOR "REBOUND" HYPERCOAGULABILITY AFTER STOPPING ANTICOAGULANTS. Lancet 1964; 2:62. [PubMed 14158680]
  • 53. Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants--a prospective study. Thromb Haemost 1994; 72:222. [PubMed 7831656]
  • 54. Genewein U, Haeberli A, Straub PW, Beer JH. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence. Br J Haematol 1996; 92:479. [PubMed 8603020]
  • 55. Kluft C, Verheijen JH, Jie AF, et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45:605. [PubMed 21444888]
  • 56. Rowbotham BJ, Whitaker AN, Harrison J, et al. Measurement of crosslinked fibrin derivatives in patients undergoing abdominal surgery: use in the diagnosis of postoperative venous thrombosis. Blood Coagul Fibrinolysis 1992; 3:25. [PubMed 3934744]
  • 57. Lip GY, Lowe GD. Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci (Lond) 1995; 89:205. [PubMed 7493413]
  • 58. Carter CJ. The pathophysiology of venous thrombosis. Prog Cardiovasc Dis 1994; 36:439. [PubMed 8184097]
  • 59. Jaffer AK, Brotman DJ, Bash LD, et al. Variations in perioperative warfarin management: outcomes and practice patterns at nine hospitals. Am J Med 2010; 123:141. [PubMed 20103023]
  • 60. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164:1319. [PubMed 15226166]
  • 61. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost 2007; 5:2211. [PubMed 17697140]
  • 62. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008; 168:63. [PubMed 18195197]
  • 63. Malato A, Saccullo G, Lo Coco L, et al. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Haemost 2010; 8:107. [PubMed 19817996]
  • 64. Spyropoulos AC, Turpie AG, Dunn AS, et al. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006; 4:1246. [PubMed 16706967]
  • 65. Spyropoulos AC, Turpie AG, Dunn AS, et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol 2008; 102:883. [PubMed 18805116]
  • 66. Steger V, Bail DH, Graf D, et al. A practical approach for bridging anticoagulation after mechanical heart valve replacement. J Heart Valve Dis 2008; 17:335. [PubMed 18592932]
  • 67. Hammerstingl C, Tripp C, Schmidt H, et al. Periprocedural bridging therapy with low- molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis 2007; 16:285. [PubMed 17578050]
  • 68. Pengo V, Cucchini U, Denas G, et al. Standardized low- molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009; 119:2920. [PubMed 19470892]
  • 69. Klamroth R, Gottstein S, Essers E, Landgraf H. Bridging with enoxaparin using a half- therapeutic dose regimen: safety and efficacy. Vasa 2010; 39:243. [PubMed 20737383]
  • 70. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S. [PubMed 18574264]
  • 71. Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 2005; 94:528. [PubMed 16268467]
  • 72. Strebel N, Prins M, Agnelli G, Büller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low- molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162:1451. [PubMed 12090880]
  • 73. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49:259. [PubMed 20214409]
  • 74. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116. [PubMed 20352166]
  • 75. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123:1436. [PubMed 21464059]
  • 76. Warkentin TE, Margetts P, Connolly SJ, et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119:2172. [PubMed 22383791]
  • 77. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:204S. [PubMed 15383473]
  • 78. O'Donnell MJ, Kearon C, Johnson J, et al. Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 2007; 146:184. [PubMed 17283349]
  • 79. Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S. [PubMed 18574274]
  • 80. Korantzopoulos P, Letsas KP, Liu T, et al. Anticoagulation and antiplatelet therapy in implantation of electrophysiological devices. Europace 2011; 13:1669. 81. Goldstein DJ, Losquadro W, Spotnitz HM. Outpatient pacemaker procedures in orally anticoagulated patients. Pacing Clin Electrophysiol 1998; 21:1730. [PubMed 21788280]

 

  top |

 

 
© 2018 Prof. Dr. J. Braun